Abstract
Psoriasis is a chronic inflammatory skin disease, and the mechanism remains unknown. The present study found that the level of miR-205-5p was downregulated in psoriatic skin tissues. miR-205-5p inhibited proliferation in HaCaT cells. miR-205-5p impaired proliferation, migration and tube formation in human umbilical vein endothelial cells. Angiopoietin (Ang)-2, vascular endothelial growth factor (VEGFA) and bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) were confirmed as the targets of miR-205-5p. Moreover, miR-205-5p suppressed the phosphorylation of p38 and extracellular regulated protein kinase, and inhibited expression level of β-catenin. In vivo, miR-205-5p significantly alleviated imiquimod (IMQ)-induced psoriasis in mice, and deactivated mitogen-activated protein kinase (MAPK) and Wnt/β-catenin pathways. In summary, we demonstrated that miR-205-5p alleviated IMQ-induced psoriasis in mice by restraining epidermal hyperproliferation and excessive neovascularization. miR-205-5p may play its roles by targeting Ang-2, VEGFA and BAMBI, and deactivating the Wnt/β-catenin and MAPK signaling pathways. These findings may provide a potential therapeutic target for clinical treatment of psoriasis.
References
Mar 26, 2005·Circulation Research·Noriyuki OuchiKenneth Walsh
May 6, 2005·The New England Journal of Medicine·Michael P Schön, W-Henning Boehncke
May 23, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Rania Harfouche, Sabah N A Hussain
Feb 23, 2007·Nature·Michelle A LowesJames G Krueger
Jul 31, 2007·Lancet·Christopher Em Griffiths, Jonathan Nwn Barker
Oct 8, 2008·The Journal of Biological Chemistry·Zhenghong LinYe-Guang Chen
Jul 31, 2009·The New England Journal of Medicine·Frank O NestleJonathan Barker
Oct 30, 2009·Autoimmunity·Ramon Alvin Chua, Jack L Arbiser
Apr 27, 2010·Journal of Dermatological Science·John R ZibertLone Skov
Nov 26, 2010·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A SalajeghehA K Y Lam
Feb 4, 2011·The Journal of Investigative Dermatology·Melissa García-CaballeroAna R Quesada
Jul 5, 2012·PloS One·Nicolas GuillotDetlef Schlondorff
Jun 27, 2013·Angiogenesis·Sebastien P TabruynIngrid Struman
Jul 13, 2013·Human Pathology·Ali SalajeghehAlfred King-Yin Lam
Sep 24, 2014·Clinical, Cosmetic and Investigational Dermatology·Ann Sophie LønnbergLone Skov
Oct 15, 2014·Cancer Letters·Nikolett M Biel, Dietmar W Siemann
Nov 29, 2014·Experimental Dermatology·Marianne B LøvendorfLone Skov
Jul 15, 2015·Gut·Jingjing QiWalter Birchmeier
Sep 6, 2015·Journal of Molecular Endocrinology·Ali SalajeghehAlfred King-Yin Lam
May 13, 2017·The Journal of Dermatology·Takehiro TakahashiShinichi Sato
Jan 11, 2018·Endocrine-related Cancer·Haleh VosghaAlfred King-Yin Lam
Jul 26, 2018·Oncotarget·Georgi AtanasovMoritz Schmelzle
Aug 14, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Madhulika Pradhan Ajazuddin
Dec 17, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Asghar FallahOmmoleila Molavi
Oct 22, 2019·Journal of Cellular and Molecular Medicine·Li-Li SunXiao-Qiang Li
Nov 23, 2019·Theranostics·Liuqing HeXiaoying Wu